SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

Stock Information for Prelude Therapeutics Incorporated

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Prelude Therapeutics Incorporated

SKYE LAWSUIT ALERT: The Gross Law Firm Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
LAWSUIT ALERT: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2026 in Skye Bioscience, Inc. Lawsuit - SKYE
Bragar Eagel & Squire, P.C. Urges DeFi, Skye Bioscience, and Perrigo Investors to Contact the Firm Regarding their Rights
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Skye Bioscience, Inc. (SKYE) Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.